EVE Health Group Limited (EVE) - Total Liabilities

Latest as of December 2025: AU$307.63K AUD ≈ $217.67K USD

Based on the latest financial reports, EVE Health Group Limited (EVE) has total liabilities worth AU$307.63K AUD (≈ $217.67K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

EVE Health Group Limited - Total Liabilities Trend (2004–2025)

This chart illustrates how EVE Health Group Limited's total liabilities have evolved over time, based on quarterly financial data. See EVE Health Group Limited current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

EVE Health Group Limited Competitors by Total Liabilities

The table below lists competitors of EVE Health Group Limited ranked by their total liabilities.

Company Country Total Liabilities
Trainers House Oyj
HE:TRH1V
Finland €2.32 Million
Goodbye Kansas Group AB (publ)
ST:GBK
Sweden Skr80.31 Million
Global Interactive Technologies, Inc
NASDAQ:GITS
USA $631.22K
Olenox Industries Inc.
NASDAQ:OLOX
USA $29.17 Million
Bank Danamon Indonesia Tbk
JK:BDMN
Indonesia Rp198.90 Trillion
LEHNER INVESTMENTS AG
F:LEH
Germany €727.60K

Liability Composition Analysis (2004–2025)

This chart breaks down EVE Health Group Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EVE company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.48 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 3.02 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.08 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.08 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how EVE Health Group Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for EVE Health Group Limited (2004–2025)

The table below shows the annual total liabilities of EVE Health Group Limited from 2004 to 2025.

Year Total Liabilities Change
2025-06-30 AU$572.45K
≈ $405.05K
-55.93%
2024-06-30 AU$1.30 Million
≈ $919.19K
+28.73%
2023-06-30 AU$1.01 Million
≈ $714.03K
-11.46%
2022-06-30 AU$1.14 Million
≈ $806.46K
-34.35%
2021-06-30 AU$1.74 Million
≈ $1.23 Million
+54.96%
2020-06-30 AU$1.12 Million
≈ $792.71K
-61.76%
2019-06-30 AU$2.93 Million
≈ $2.07 Million
+3715.34%
2018-06-30 AU$76.80K
≈ $54.34K
-73.84%
2017-06-30 AU$293.55K
≈ $207.71K
+71.38%
2016-06-30 AU$171.29K
≈ $121.20K
+32.70%
2015-06-30 AU$129.08K
≈ $91.33K
+52.91%
2014-06-30 AU$84.42K
≈ $59.73K
+6.55%
2013-06-30 AU$79.23K
≈ $56.06K
-87.72%
2012-06-30 AU$644.97K
≈ $456.35K
-37.95%
2011-06-30 AU$1.04 Million
≈ $735.46K
-15.66%
2010-06-30 AU$1.23 Million
≈ $871.98K
+208.56%
2009-06-30 AU$399.39K
≈ $282.60K
-66.51%
2008-06-30 AU$1.19 Million
≈ $843.81K
+86.01%
2007-06-30 AU$641.12K
≈ $453.63K
+101.94%
2006-06-30 AU$317.49K
≈ $224.64K
+15.46%
2005-06-30 AU$274.98K
≈ $194.57K
+90.98%
2004-06-30 AU$143.99K
≈ $101.88K
--

About EVE Health Group Limited

AU:EVE Australia Packaged Foods
Market Cap
$5.44 Million
AU$7.69 Million AUD
Market Cap Rank
#28387 Global
#1513 in Australia
Share Price
AU$0.02
Change (1 day)
+4.76%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.04
About

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erect… Read more